Chicago, IL 的 淋巴瘤 臨床試驗
20 項針對 淋巴瘤 的研究正在 Chicago（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
招募中2 期
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
招募中1/2 期
- Lurie Children's Hospital-Chicago, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
招募中3 期
- Research Site, Chicago
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
招募中1 期
- University of Illinois Cancer Center, Chicago
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
招募中1/2 期
- University of Chicago, Chicago
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
招募中1/2 期
- University of Chicago Medical Center, Chicago
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
招募中1 期
- The David and Etta Jonas Center for Cellular Therapy, Chicago
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
招募中3 期
- Northwestern, Chicago
- University of Chicago, Chicago
Mosaic Trial for Stem Cell Transplant Recipients
招募中
- Northwestern University Feinberg School of Medicine, Chicago
DALY II USA/ MB-CART2019.1 for DLBCL
招募中2 期
- Robert H Lurie Cancer Center, Chicago
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
招募中1/2 期
- Call for Information (Investigational Site 0024), Chicago
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
招募中1 期
- Northwestern University, Chicago
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
招募中觀察性研究
- Lurie Children's Hospital-Chicago, Chicago
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
招募中1/2 期
- Northwestern Memorial Hospital, Chicago
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
招募中1/2 期
- University of Illinois at Chicago Cancer Center, Chicago
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
招募中1 期
- The University of Chicago Medical Center, Chicago
CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL
招募中1/2 期
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
招募中
- University of Chicago Comprehensive Cancer Center, Chicago
Avo In R/R And Previously Untreated MCL
招募中1/2 期
- University of Chicago Medical Center, Chicago
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
招募中1 期
- Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago
其他城市的 淋巴瘤 試驗
- Houston, TX34 項研究
- Boston, MA33 項研究
- New York City, NY33 項研究
- Washington, DC23 項研究
- Baldwin Park, CA21 項研究
- Durham, NC17 項研究
- St. Louis, MO15 項研究
- Philadelphia, PA15 項研究
- Cleveland, OH14 項研究
- Edison, NJ12 項研究
- Atlanta, GA12 項研究
- Seattle, WA12 項研究
Chicago 的其他研究
- 非小細胞肺癌61 項研究
- 乳癌58 項研究
- 癌症（所有類型）51 項研究
- 轉移性癌症45 項研究
- 前列腺癌45 項研究
- 肥胖症41 項研究
- 肺癌41 項研究
- 卵巢癌36 項研究
- 中風34 項研究
- 大腸直腸癌33 項研究
- 心臟衰竭31 項研究
- 過重28 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。